Biotech RadarJobs updated

COMPANY

Rivus Pharmaceuticals

HQ: Charlottesville, VA source · rivuspharma.com ↗ · West Coast

Clinical Phase 2

Keywords: metabolic NASH - Nonalcoholic Steatohepatitis MASH - Metabolic Dysfunction-Associated Steatohepatitis Overweight Non-Alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis Fatty Liver Heart Failure With Preserved Ejection Fraction Diabete Type 2 Obesity Obese HU6 [14C]-HU6

Location: Charlottesville, VA · source · Jan 16, 2025

Profile checked Oct 10, 2026

11Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) source ↗
  2. Trial start 1: Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6 source ↗
  3. Trial start Phase 1: Relative Bioavailability Study of HU6 source ↗
  4. Trial start Phase 1: A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6 source ↗
  5. Trial start Phase 2: Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes source ↗
  6. Trial start Phase 2: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis source ↗
  7. Trial start Phase 2: Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF source ↗
  8. Trial start Phase 1: Safety and Pharmacokinetics of HU6 source ↗
  9. Trial start 2: Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers source ↗
  10. Trial start Phase 1: Multiple Ascending Dose Study of HU6 in High BMI Volunteers source ↗
  11. Trial start Phase 1: Ascending Dose Study of HU6 in Healthy Volunteers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT07491458A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)Phase 2RecruitingFeb 13, 20262027-02 (estimated)
NCT07170189Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU61CompletedOct 13, 2025Dec 4, 2025 (actual)
NCT06486558Relative Bioavailability Study of HU6Phase 1CompletedJul 24, 2024Nov 15, 2024 (actual)
NCT05979779Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic SteatohepatitisPhase 2Active, not recruitingSep 5, 2023Jan 21, 2025 (actual)
NCT05284617Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEFPhase 2CompletedOct 30, 2022May 24, 2024 (actual)
NCT06325930A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6Phase 1CompletedMar 26, 2024May 7, 2024 (actual)
NCT04874233Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers2CompletedApr 19, 2021Nov 30, 2021 (actual)
NCT06104358Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 DiabetesPhase 2WithdrawnNov 17, 20232025-02 (estimated)
NCT05433506Safety and Pharmacokinetics of HU6Phase 1CompletedSep 15, 2022Jan 30, 2023 (actual)
NCT04709913Multiple Ascending Dose Study of HU6 in High BMI VolunteersPhase 1CompletedJan 4, 2021Apr 30, 2021 (actual)
NCT04463017Ascending Dose Study of HU6 in Healthy VolunteersPhase 1CompletedAug 12, 2020Mar 30, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback